Cerebral blood volume estimation by ferumoxytol-enhanced steady-state MRI at 9.4 T reveals microvascular impact of $\alpha_1$-adrenergic receptor antibodies

Andreas Pohlmann$^{a*,†}$, Peter Karczewski$^{b†}$, Min-Chi Ku$^a$, Babette Dieringer$^a$, Helmar Waiczies$^{a,c}$, Natali Wisbrun$^d$, Stefanie Kox$^a$, Irina Palatnik$^a$, Henning Matthias Reimann$^a$, Christina Eichhorn$^e$, Sonia Waiczies$^{a,c}$, Petra Hempel$^b$, Bernd Lemke$^b$, Thoralf Niendorf$^{a,c‡}$ and Marion Bimmler$^{f‡}$

Cerebrovascular abnormality is frequently accompanied by cognitive dysfunctions, such as dementia. Antibodies against the $\alpha_1$-adrenoceptor ($\alpha_1$-AR) can be found in patients with Alzheimer’s disease with cerebrovascular disease, and have been shown to affect the larger vessels of the brain in rodents. However, the impact of $\alpha_1$-AR antibodies on the cerebral vasculature remains unclear. In the present study, we established a neuroimaging method to measure the relative cerebral blood volume (rCBV) in small rodents with the ultimate goal to detect changes in blood vessel density and/or vessel size induced by $\alpha_1$-AR antibodies. For this purpose, mapping of $R_2^*$ and $R_2$ was performed using MRI at 9.4 T, before and after the injection of intravascular iron oxide particles (ferumoxytol). The change in the transverse relaxation rates ($\Delta R_2^*$, $\Delta R_2$) showed a significant rCBV decrease in the cerebrum, cortex and hippocampus of rats (except hippocampal $\Delta R_2$), which was more pronounced for $\Delta R_2^*$ than for $\Delta R_2$. Immunohistological analyses confirmed that the $\alpha_1$-AR antibody induced blood vessel deficiencies. Our findings support the hypothesis that $\alpha_1$-AR antibodies lead to cerebral vessel damage throughout the brain, which can be monitored by MRI-derived rCBV, a non-invasive neuroimaging method. This demonstrates the value of rCBV estimation by ferumoxytol-enhanced MRI at 9.4 T, and further underlines the significance of this antibody in brain diseases involving vasculature impairments, such as dementia. Copyright © 2014 John Wiley & Sons, Ltd.

Keywords: MRI; cerebral blood volume (CBV); ferumoxytol; ultrasmall superparamagnetic iron oxide (USPIO); $\alpha_1$-adrenergic receptor antibody; rat

INTRODUCTION

Cerebrovascular disease, a group of pathological processes affecting the small arteries, arterioles, venules and capillaries of the brain (1), is frequently accompanied by cognitive dysfunction. Although it remains challenging to determine the contribution of cerebrovascular disease to cognitive impairment, or vice versa, accumulating evidence indicates that cerebrovascular disease might be an important cause of cognitive dysfunction and neurodegeneration,
such as dementia (2). The findings of structural and functional changes of cerebral blood vessels suggest that brain microcirculation abnormalities might contribute to Alzheimer’s disease (AD) (3). Clinical studies focusing on cerebrovascular pathologies have shown that autoantibodies against the α1-adrrenergic receptor (α1-AR) with agonist-like activity can be found in patients with hypertension (4,5), as well as in patients with AD with cerebrovascular disease (6), suggesting that the observed vascular symptoms might be induced by the α1-AR antibody (7,8). α1-AR is a member of the G-protein-coupled receptor superfamily which mediates the physiological responses to norepinephrine and epinephrine, which regulate several important cardiovascular actions (9), and has been found to be expressed on human cerebral blood vessels (10). Vascular impairments in the larger vessels of the rat brain after exposure to the α1-AR antibody have been shown recently by time-of-flight MR angiography (11). However, this approach is not able to depict blood vessels significantly smaller in diameter than the spatial resolution (~100 μm) in this study – so that the impact of α1-AR on the cerebral vasculature, in particular the microvasculature down to the capillary level, is still unknown. Realizing the challenges and opportunities of probing for subtle cerebrovascular changes in experimental in vivo models, it is conceptually appealing to pursue non-invasive cerebral blood volume (CBV) mapping techniques that allow for longitudinal in vivo studies.

MRI enables the non-invasive estimation of the relative cerebral blood volume (rCBV) and hence the detection of changes in blood vessel density and/or vessel size. Tracking the signal intensity–time curve during bolus injection of gadolinium-based contrast agents is the clinical standard for rCBV assessment (12). This approach requires MRI with high temporal resolution and inherently limited spatial resolution. If the blood–brain barrier is compromised, leakage of the contrast agent into the interstitial space is a confounding factor (13). Intravascular contrast agents, such as ultrasmall superparamagnetic iron oxides (USPIOs), represent an attractive alternative for rCBV assessment with MRI (14). The long plasma half-life and tendency to remain intravascular of USPIO facilitates steady-state measurements, yielding more accurate rCBV estimation (15,16). For rCBV estimation pre-/post-change, contrasts in the effective transverse relaxation rate (R2*) are used, assuming a linear dependence of R2* on the USPIO blood plasma concentration (∆R2* = rCBV) (17–19).

Lately, the (pre-)clinical use of USPIOs as MRI contrast agents is being hindered by the unavailability of various commercial USPIOs (e.g. Resovist®, Feridex®/Endorem®, Combidex®/Sinerem® have been discontinued), leaving no Food and Drug Administration (FDA)-approved USPIO contrast agent available for clinical MRI (20). Ferumoxytol (Feraheme®) is a USPIO that has been FDA approved as an intravenous iron supplement for the treatment of anemia in patients with chronic kidney disease (21). Ferumoxytol’s non-toxicity, even at high doses, and long blood plasma half-life of approximately 15 h in humans (Feraheme® injection label, FDA) and >2 h in rats (20,22) make it well suited as an intravascular MRI contrast agent. To date ferumoxytol’s potential for rCBV measurements remains largely untested, with only a few reports of its use in humans (13,23–26) and small rodents (16,27,28). Despite its early application in rat brain MRI (29), ferumoxytol-enhanced rCBV measurements at the common pre-clinical MRI system field strength of 9.4 T have not been reported to date.

In this work, we aimed to establish the feasibility of rCBV monitoring in rats by ferumoxytol-enhanced MRI at 9.4 T and to demonstrate, for the first time, α1-AR antibody-induced cerebral microvascular impairments by the application of this technique. Analysis of ∆R2* and ∆R1 showed a significant decrease in rCBV in the cerebrum, cortex and hippocampus in rats, suggesting a strong impact of α1-AR antibodies on the cerebral microvasculature.

**MATERIALS AND METHODS**

**Animal model**

Male Wistar rats (10–13 weeks of age; 280–350 g) were purchased from Charles River Laboratories, Sulzfeld, Germany. All animal experiments were approved and carried out in accordance with the regulation and guidelines provided by the Animal Welfare Department of the Landesamt für Gesundheit und Soziales Berlin (Berlin State Office of Health and Social Affairs, Permit Number: G0197/10). Eighteen rats were randomly allocated to two experimental groups, with nine rats in each. One group received intravenous injections of α1-AR antibodies (700 mg/kg body weight), prepared as described in ref. (11). The corresponding control group was injected with the same dose of control immunoglobulin G (IgG). The injections were repeated monthly. To measure the antibody concentration, blood serum was obtained as described previously (11). All rats were anesthetized by inhalation of isoflurane in air throughout the entire imaging experiment.

**Ferumoxytol particle size analysis and dose optimization**

In vitro analysis of ferumoxytol and in vivo pilot MRI measurements were carried out to establish the suitability of ferumoxytol for off-label use as an intravascular MRI contrast agent for rat CBV monitoring at 9.4 T. As the magnetic properties of USPIOs depend on their particle size, production batches with different particle sizes may have different magnetic properties (14). In order to determine the particle size variability between batches of ferumoxytol, particle size analysis of samples taken from three separately purchased 17-ml Feraheme® vials (AMAG Pharmaceuticals, Inc., Lexington, MA, USA) was performed by dynamic light scattering (Malvern Zetasizer Nano ZS instrument, Malvern Instruments, Malvern, Worcestershire, UK).

To determine a ferumoxytol dose suitable for rat rCBV measurements at 9.4 T, initial titration experiments were performed in two animals for dose calibration. Following baseline T2 and T2* mapping, four consecutive doses of 5 mg of Fe/kg ferumoxytol (Feraheme®, AMAG Pharmaceuticals, Inc.) were administered using a power injector at an infusion rate of 0.25 ml/min via a tail vein catheter. Parametric mapping was repeated after each injection, i.e. at 5, 10, 15 and 20 mg of Fe/kg ferumoxytol.

The time courses of T2*, T2 and T2*-weighted image intensity were monitored in two animals for approximately 100 min following a single dose of 10 mg of Fe/kg ferumoxytol to confirm a sufficiently slow temporal change in plasma concentration that allows for post-injection T2 and T2* mapping during a period of approximately 15 min after contrast agent administration.

**Study design**

Eighteen rats underwent MRI at 9 and 11 months after treatment (α1-AR antibodies or IgG) had commenced. Following baseline T2 and T2* mapping, 10 mg of Fe/kg ferumoxytol (Feraheme®, AMAG Pharmaceuticals, Inc.) was administered using a power
injected at a rate of 0.25 mL/min via a tail vein catheter. Following a 3-min mixing time starting from the end of injection, $T_2$ and $T_2^*$ mapping was repeated.

**MRI**

Animals were anesthetized with isoflurane (1.8–2.0% in air), the tail vein was catheterized and the animal was transferred to the warmed animal holder of a horizontal 9.4-T small-bore (20-cm) animal MR system (Biograph 94/20, Bruker Biospin, Ettlingen, Germany). The MR system was equipped with a linear polarized birdcage radiofrequency (RF) resonator for transmission, in conjunction with a curved four-channel receive RF coil array (Bruker Biospin) customized for rat brain imaging.

For $T_2^*$ mapping used a multigradient echo (MGE) sequence ($TR = 620 \text{ ms}; TEs = 8$; first $TE = 2.14 \text{ ms};$ TE increment = 2.14 ms; averages, 2; positive spoiler gradient of 20% strength and 1.43 ms in duration) with a total acquisition time of 4 min. TEs were chosen to be integral multiples of 0.7137 ms at which water and fat are in phase (based on the measured fat–water frequency shift). For $T_2$ mapping, a multislice multipspin echo (MSME) sequence ($TR = 2000 \text{ ms}; TEs = 7$; first $TE = 9.99 \text{ ms};$ TE increment = 9.99 ms; positive spoiler gradient of 20% strength and 0.5 ms in duration) was employed, with a total acquisition time of 6 min. For $T_2^*$ and $T_2$ mapping, 21 consecutive coronal slices covering the entire brain were acquired with an in-plane spatial resolution of $(137 \times 137) \mu\text{m}^2$, field of view of $(35 \times 35) \text{ mm}^2$, matrix size of 256×256 and slice thickness of 1.0 mm.

**Image analysis**

Parametric maps of absolute $T_2^*$ and $T_2$ were calculated by pixel-wise mono-exponential fitting to the signal intensities of denoised series (SANLM filter, VBM8 toolbox, SPM8, www.fil.ion.ucl.ac.uk/spm) of $T_2^*$- and $T_2$-weighted images acquired as a function of TE (in-house developed program; MATLAB, R2010a, MathWorks, Natick, WA, USA). Relaxation times as a function of TE (in-house developed program; MATLAB, R2010a, MathWorks, Natick, WA, USA). Relaxation times $T_2^*$ and $T_2$ were converted to their corresponding relaxivities, $R_2^* = 1/T_2^*$ and $R_2 = 1/T_2$, and subtraction of pre-contrast maps from post-contrast maps yielded parametric $\Delta R_2^*$ and $\Delta R_2$ maps.

Volume of interest (VOI) analysis using ImageJ (National Institutes of Health, Bethesda, MD, USA; http://imagej.nih.gov/ij) was performed on all datasets for which: (i) it was certain that the entire target volume of ferromyxotol had been injected intravenously; and (ii) the parametric mapping yielded brain tissue $T_2^*$ values in the range 1–50 ms (10–100 ms). For all animals, the cerebrum was extracted by manual segmentation of all 21 coronal slices using the longest TE image ($TE_{\text{MSME}} = 69.93 \text{ ms}$, $TE_{\text{MGE}} = 17.12 \text{ ms}$). This was followed by an automated division of each segmented brain map into dorsal and ventral halves. Further quantitative analysis was applied only to the dorsal brain half, hence excluding ventral brain regions that were influenced by macroscopic susceptibility artifacts originating from ventral cavities outside the brain. In addition to the dorsal cerebrum, two further VOIs were defined by manual segmentation of the cortex and hippocampus, based on pre-contrast $T_2$-weighted images ($TE_{\text{MSME}} = 69.93 \text{ ms}$) and post-contrast $T_2^*$-weighted images ($TE_{\text{MGE}} = 6.42 \text{ ms}$), respectively.

Histograms of $\Delta R_2^*$ and $\Delta R_2$ were obtained from the parametric maps generated for each VOI and animal. Histogram counts were averaged over the animals in each group (mean ± standard error of the mean (SEM)), after normalization (division by total number of counts, multiplication by 10,000), eliminating the dependence on the number of voxels within each VOI. Plots of the empirical cumulative frequency were used instead of common histograms, as they make shifts in the $\Delta R_2^*$ ($\Delta R_2$) distributions towards lower/higher values more apparent. Cumulative frequency plots can be interpreted as integrals of histograms, and their frequencies range from ‘0’ to ‘1’ (equivalent to 100%).

For quantitative comparison between two parameter distributions ($\alpha_1$-AR antibody group versus control group), the supremum of the absolute differences was derived from the cumulative frequencies ($F_2$): $d_{\text{max}} = \sup |F_2(\Delta R_2^*) – F_2(\Delta R_2^*)_{\text{control}}|$. The parameter $d_{\text{max}}$ is also the basis of the statistical analysis (Kolmogorov–Smirnov test).

**Blood vessel immunofluorescent staining and image processing**

After the final MRI time point, the deeply anesthetized rats were perfused with 0.9% NaCl, followed by 4% paraformaldehyde. Brain tissues were removed and post-fixed overnight in 4% paraformaldehyde. Dehydrated specimens were embedded in paraffin using standard methods. Paraffin sections were dewaxed, rehydrated and antigen retrieval was performed by heating sections at 98 °C in citrate buffer at pH 6.0. For the identification of cerebral blood vessels, a primary antibody against rat CD31 was added overnight at a dilution of 1:50 (Abcam PLC, Cambridge, UK) at 4 °C. Alexa 594-conjugated goat anti-rabbit IgG (1:200, Invitrogen, Carlsbad, CA, USA) was subsequently applied. The nuclei were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich, Seelze, Germany). Images were taken using a confocal microscope (LSM 710, Zeiss, Jena, Germany) with 10× or 20× lenses. Care was taken to select an anatomically similar cortical region for all animals.

CD31-positive-labeled blood vessel staining was quantified using ImageJ (National Institutes of Health). After thresholding of the red color channel, the fraction of CD31-positive pixels was counted, yielding the vessel area fraction. From these thresholded red channel images, we derived two further parameters as qualitative surrogates of vessel density and vessel size. Employing binary region growing (2x) to the thresholded images, disconnected positive pixels located in the vessel walls were merged into clusters/objects. Use of the 3D Objects Counter plugin for ImageJ provided the cluster count; division by the image field of view yielded the CD31 cluster density. CD31 cluster size was calculated by dividing the vessel area fraction by the CD31 cluster density.

**Statistical analysis**

$\Delta R_2^*$ and $\Delta R_2$ values derived from the three VOIs were statistically analyzed by testing for a significant difference in the parameter distributions using a two-sample Kolmogorov–Smirnov test, which is sensitive to differences in the location and shape of two empirical cumulative distribution functions. A probability value of less than 0.05 was considered to be significant for differences between groups.

Statistical analysis of the quantitative blood vessel immunofluorescent staining data was performed using a one-sided t-test, with a probability value of less than 0.05 being considered as significant.
RESULTS

Ferumoxytol particle size analysis and dose optimization

Particle size analysis of samples taken from three separately purchased 17-mL Feraheme® vials showed that ferumoxytol has an average colloidal particle size of 23.38 ± 0.37 nm (zeta-average). The particle size distribution was narrow (Fig. 1A), ranging from 10 to 70 nm with a small polydispersity index of 0.11 ± 0.02, and did not show secondary peaks in addition to the main peak depicted in Fig. 1A.

In vivo, the rat brain relaxation times $T_2^*$ and $T_2$ decreased rapidly with increasing dose of ferumoxytol (Fig. 1B). Owing to its non-linear dose dependence, the $T_2^*$ reduction per consecutive dose of 5 mg Fe/kg declined, and total doses of 15 and 20 mg Fe/kg only translated into modest relaxation time changes compared with 10 mg Fe/kg. As local blood plasma concentrations of ferumoxytol ($c$) are unknown, the molar relaxivities $r_2^*$ and $r_2$ of ferumoxytol cannot be derived from the in vivo observed effects on $R_2^*$ or $R_2$ (where, for example, $\Delta R_2 = r_2^*CBV$). Nevertheless, reporting the systemic dose relaxivities $r_2^{SD}$ and $r_2^{SD}$ (where, for example, $\Delta R_2 = r_2^{SD}CBV$) with regard to the systemically administered iron dose ($d_i$) may be useful for researchers interested in employing similar protocols. $r_2^{SD}$ and $r_2^{SD}$ of ferumoxytol for the cortex and subcortical region were approximately $r_2^{SD,cortex} = 6.6 \text{s}^{-1} \text{mg}^{-1} \text{kg}$, $r_2^{SD,sub} = 6.0 \text{s}^{-1} \text{mg}^{-1} \text{kg}$ and $r_2^{SD,cortex} = 0.34 \text{s}^{-1} \text{mg}^{-1} \text{kg}$, $r_2^{SD,sub} = 0.28 \text{s}^{-1} \text{mg}^{-1} \text{kg}$, as derived from linear regression to $R_2^*$ ($R_2$) versus ferumoxytol dose curves (Fig. 1D), with fitting qualities of $R^2 = 1.00$, 0.98, 1.00 and 0.97, respectively.

Time courses of $T_2$, $T_2^*$ and the $T_2^*$-weighted signal for regions of interest placed in the cortex and subcortical regions are shown in Fig. 1C. During and after contrast agent injection, a strong signal intensity decrease was observed in the $T_2^*$-weighted images ($\Delta SI = -32\%$ with 10 mg Fe/kg), as demonstrated in Fig. 1C for a region of interest placed in the cortex, and as illustrated in Figure 2B in comparison with Fig. 2A also for the entire coronal slice of the rat brain. Examination of the parameter maps revealed a decrease in $T_2^*$ and $T_2$ throughout the brain ($\Delta T_2^*_{cortex} = -67\%$, $\Delta T_2_{cortex} = -17\%$), as demonstrated in the plots of $T_2/T_2^*$ versus time (Fig. 1C) and in the color-coded $\Delta R_2^*$ and $\Delta R_2$ parameter maps (Fig. 2C, F). For illustration, all 21 coronal $T_2^*$-weighted and $T_2^*$-weighted slices derived from a rat brain after injection of 10 mg Fe/kg ferumoxytol are shown in Figs S1 and S2, respectively, together with the corresponding $\Delta R_2$ and $\Delta R_2^*$ maps. In the 100 min following contrast agent injection, $R_2^*$ and $R_2^*$ increased by merely 0.18%/min and 0.03%/min, respectively.

rCBV in α1-AR antibody-exposed animals versus controls

Histograms of $\Delta R_2^*$ in the dorsal cerebrum at 9 months (Fig. 3A) and 11 months (Fig. 3B) after treatment began revealed that histogram counts above $\Delta R_2^* \approx 75 \text{ms}$ were decreased in the α1-AR antibody group compared with the control group, whereas counts below $\Delta R_2^* \approx 75 \text{ms}$ were increased. This translates into a shift of $\Delta R_2^*$ towards lower values, which becomes more apparent when the cumulative frequency (Fig. 3C, D) is used. At 9 months (Fig. 3C, E) and 11 months (Fig. 3D, F), $\Delta R_2^*$ and $\Delta R_2$ in the dorsal cerebrum were found to be significantly reduced for the α1-AR antibody group in comparison with the control group.

Figure 1. (A) Size distribution for a sample of ferumoxytol nanoparticles obtained from particle size analysis by dynamic light scattering. The average colloidal particle size for samples from all three vials was 23.38 ± 0.37 nm (zeta-average, logarithmic scale). (B, D) Plots of $T_2^*$, $T_2$ and $R_2^*$ versus iron dose for regions of interest placed in the cortex and subcortical regions. (C) Time courses of $T_2$, $T_2^*$ and the $T_2^*$-weighted (T2w) signal intensity (right axis) for regions of interest in the cortex and subcortical regions from pre-contrast to approximately 2 h after intravenous injection of 10 mg Fe/kg ferumoxytol.
Figure 2. (A, B) Coronal $T_2$-weighted ($T_2$ w) images ($TE = 30$ ms) of a rat brain before (A) and after (B) injection of 10 mg Fe/kg ferumoxytol. The outline of the dorsal cerebrum (DC) volume of interest (VOI) is shown in red. (C) Color-coded $\Delta R_2$ map. (D, E) $T_2^*$-weighted images ($TE = 6.4$ ms) pre-contrast (D) and post-contrast (E). The outlines of the cortex (C) and hippocampus (H) VOIs are shown in red. The vessels running into the cortex can clearly be seen in (D). (F) Color-coded $\Delta R_2^*$ map. USPIO, ultrasmall superparamagnetic iron oxide.

Figure 3. (A, B) Histograms of $\Delta R_2^*$ in the dorsal cerebrum at 9 months (A) and 11 months (B) after treatment began. Mean ± standard error of the mean (SEM) for the $\alpha_1$-adrenoceptor ($\alpha_1$-AR) antibody group (red) and the control immunoglobulin G (IgG) group (black). At both time points, the histogram counts above $\Delta R_2^* \approx 75$ ms are decreased in the $\alpha_1$-AR antibody group compared with the control group, whereas counts below $\Delta R_2^* \approx 75$ ms are increased. This translates into a shift of $\Delta R_2^*$ towards lower values. (C, D) Corresponding plots of the cumulative frequency of $\Delta R_2^*$ in the dorsal brain at 9 months (C) and 11 months (D). (E,F) Cumulative frequency of $\Delta R_2$ in the dorsal cerebrum at 9 months (E) and 11 months (F). (C–F) The leftward shift of the cumulative frequencies represents a significant reduction in $\Delta R_2^*$ and $\Delta R_2$ in the dorsal cerebrum with $***p < 0.001$. $d_{\max}$ is the supremum of the absolute differences between the cumulative frequencies of both groups.
control IgG group ($p < 0.001$). The maximum differences $d_{\text{max}}$ between the cumulative frequency of both groups at 11 months were 7.0% and 2.8% for $\Delta R_2^*$ and $\Delta R_2$, respectively.

A similar shift towards lower $\Delta R_2^*$ and $\Delta R_2$ in the $\alpha_1$-AR antibody group was observed in the cortex (Fig. 4A–D) and hippocampus (Fig. 4E–H) at both time points ($p < 0.001$), with the exception of $\Delta R_2$ in the hippocampus at 11 months. $d_{\text{max}}$ values for the cortex at 11 months were larger ($\Delta R_2^*$, 8.3%; $\Delta R_2$, 3.4%) than for the entire dorsal cerebrum. In the hippocampus, $d_{\text{max}}$ for $\Delta R_2^*$ (8.8%) was even higher, but $d_{\text{max}}$ for $\Delta R_2$ (0.3%) was smaller and non-significant.

**Blood vessel immunofluorescent staining**

Blood vessel immunofluorescent staining showed a strongly reduced CD31 staining in the cortex of animals exposed to the $\alpha_1$-AR antibody (Fig. 5A, bottom panel) relative to the IgG controls (Fig. 5A, top panel). Quantitative analysis of the immunofluorescence images indicated a significant decrease in CD31 vessel area (56%, $p < 0.05$; Fig. 5B), i.e. the area fraction with positive CD31 staining for the $\alpha_1$-AR antibody compared with the IgG controls. The CD31 cluster density (Fig. 5C) and CD31 cluster size (Fig. 5D) were reduced in the $\alpha_1$-AR antibody group by 44% and 27%, respectively (both non-significant).

---

Figure 4. Cumulative frequencies of $\Delta R_2^*$ (A, B, E, F) and $\Delta R_2$ (C, D, G, H) in the cortex (A–D) and hippocampus (E–H) at 9 months (A, C, E, G) and 11 months (B, D, F, H) after treatment began. Mean for the $\alpha_1$-adrenoceptor ($\alpha_1$-AR) antibody group (red) and the control immunoglobulin G (IgG) group (black). A significant reduction in $\Delta R_2^*$ and $\Delta R_2$ ($**p < 0.001$) was observed in both cortex and hippocampus at all time points, with the exception of $\Delta R_2$ in the hippocampus at 11 months. $d_{\text{max}}$ is the supremum of the absolute differences between the cumulative frequencies of both groups.
DISCUSSION

Ferumoxytol particle size analysis and dose optimization

The particle size analysis of different Feraheme® vials showed that ferumoxytol’s average colloidal particle size is 23.38 ± 0.37 nm (instrument accuracy, ±2%) and hence 22% smaller than the commonly cited 30 nm (15). More importantly, the average size variation between batches was very small (standard deviation, 1.6%; instrument precision, ±2%) and the samples were monomodal (i.e. only one peak) and monodisperse (i.e. very narrow width of distribution). These are prerequisites for use as an intravascular contrast agent in rCBV studies, as the magnetic properties of USPIOs depend on their particle size (14).

The subsequent pilot MRI experiments demonstrated that the use of ferumoxytol as an intravascular contrast agent for rat rCBV mapping at 9.4 T is feasible: increasing doses of ferumoxytol led to a strong decrease in $T_2^*$ and $T_2$ of rat brains, which could easily be detected with $T_2^*(T_2)$-weighted MRI and $T_2^*(T_2)$ mapping. With increasing iron dose, a linear rise in $R_2^*$ and sublinear rise in $R_2$ were observed; this is in agreement with previous findings for AMI-227 (Sinerem®, Guerbet, France), an USPIO contrast agent of similar size (30). For CBV estimation based on single-echo $T_2^*$- or $T_2$-weighted imaging, an optimal iron dose can be derived from contrast-to-noise measurements (31). However, no equivalent approach exists for multi-echo parametric mapping of $T_2^*$ and $R_2$, as employed in this study. Balancing the constraints of the signal-to-noise ratio of the first five gradient echo images (TE = 2.1–10.7 ms), which decreases with increasing ferumoxytol dose, and rCBV measurement sensitivity, which increases with ferumoxytol dose, a dose of 10 mg Fe/kg was chosen for the rCBV measurements. This dose is slightly higher than the 3.8–9.0 mg Fe/kg dose that has been used previously for rat rCBV measurements at 11.75 T (16,27,28).

The advantage of the slow washout of ferumoxytol is that MR image acquisitions post-injection do not need to be started with ‘second’ precision: for instance, during a 30-s delay, cortical $R_2^*$ will increase by less than 0.1%. Ferumoxytol’s sufficiently high relaxivities and iron concentration allow for small volume doses. All these characteristics indicate that ferumoxytol is well suited as an intravascular contrast agent for longitudinal rCBV studies in rats at 9.4 T.

CBV in $\alpha_1$-AR antibody-exposed animals versus controls

Ferumoxytol-enhanced steady-state rCBV estimation revealed significant differences in the relaxivities $\Delta R_2^*$ and $\Delta R_2$ of $\alpha_1$-AR antibody-exposed rats relative to the control group. Although the differences were small, the statistical analysis showed...
that the chance of obtaining such differences between two random groups from the naive animal population were very small \( (p < 0.001); \) see also the small SEMs in Fig. 3A, B or compare with the non-significant group difference shown in Fig. 4H. \( \alpha_1 \)-AR antibodies induced a widespread rCBV reduction, observed as reductions in the cerebral \( \Delta R_2^* \) and \( \Delta R_2 \) at 9 and 11 months of treatment. More detailed analysis of the subregions within the cerebrum showed similarly large effects in the cortex and hippocampus, which are important in the context of dementia. \( \alpha_1 \)-ARs are found in the hippocampus, where animal studies have shown the ability of \( \alpha_1 \)-AR agents to modulate long-term potentiation and memory (32). However, the precise distribution of \( \alpha_1 \)-AR expression and its subtypes in the human brain are unknown, making functional comparisons challenging (33). It remains to be clarified whether the observed impacts of \( \alpha_1 \)-AR antibodies on rCBV in rats are associated with impairments in cognitive function, which is possible as the same antibodies have also been detected in patients with Alzheimer’s disease with cerebral vascular disease (34), where it has been suggested that the vascular symptoms could be induced by the \( \alpha_1 \)-AR antibody (7,8). As the \( \Delta R_2^* \)-based rCBV effects are of similar magnitude in the cortex and hippocampus as in the entire dorsal cerebrum, effects in these subregions must be accompanied by rCBV reductions in other subregions of the dorsal cerebrum.

\( \Delta R_2^* \)-based and \( \Delta R_2 \)-based rCBV estimates showed some dissimilarities, for instance \( \Delta R_2^* \) but not \( \Delta R_2 \) was significantly reduced in the hippocampus. Dissimilar findings in \( \Delta R_2^* \) and \( \Delta R_2 \) might be explained by their respective dependences on the size and structure of the vascular compartment (17,30), which was also the motivation for measuring both parameters in this study. Although the USPIO-induced magnetic field inhomoogeneity within voxels results directly in a \( \Delta R_2^* \) decrease as a result of reversible spin dephasing, the USPIO effect on \( \Delta R_2 \) depends on the intravascular–extravascular diffusional motion of water creating irreversible spin dephasing. This translates into rather different vessel size dependences, with \( \Delta R_2^* \) having similar sensitivity to all vessel sizes and \( \Delta R_2 \) being predominantly sensitive to small arterioles, venules and capillaries of the brain (17). It should also be noted that \( \Delta R_2 \) might be underestimated as a result of using a multi-echo, spin-echo protocol with short inter-echo times of 10 ms, which interferes with the effective water diffusion contribution (14,35).

Moreover, in addition to the desired dependence of the transverse relaxivities on the vascular volume fraction and contrast agent concentration, variations in hematocrit are a potentially confounding factor. USPIOs are only present in the plasma volume fraction of the blood and not in the erythrocyte volume fraction. Hence, USPIO-enhanced MRI estimates cerebral plasma volume rather than blood volume. The hematocrit is known to be lower in the microvasculature because of plasma skimming (36), which translates into a larger plasma volume fraction and hence a higher USPIO blood concentration. Blood volume (and its changes) at the capillary level may therefore be overestimated when compared with larger vessels.

Although we observed a significant \( \alpha_1 \)-AR antibody impact on cortical \( \Delta R_2^* \) and \( \Delta R_2 \) in the hippocampus, \( \Delta R_2^* \), but not \( \Delta R_2 \), was reduced. Keeping in mind the different vessel size dependence of \( \Delta R_2^* \) and \( \Delta R_2 \), this might be caused by a different balance between \( \alpha_1 \)-AR antibody effects in small and large vessels in the hippocampus, but the mechanisms behind these findings remain to be unraveled.

The anesthetic’s known intrinsic vasodilatory action may have led to a global increase in CBV (37,38). This effect may have translated into a global overestimation of CBV for the animals of both groups, but we cannot rule out that it may also have contributed to the differentiation of both groups if the \( \alpha_1 \)-AR antibody also impacted on the dilatory ability of the vasculature, i.e. the cerebrovascular reactivity (CVR). Conceivably, isoflurane anesthesia could be interpreted as a vasodilatory challenge, resulting in CBV and CVR effects of the \( \alpha_1 \)-AR antibody causing the observed rCBV group differences.

\( \Delta R_2^* \) reflects the local USPIO blood plasma concentration, but it can only be a surrogate of CBV as the exact blood concentration of the contrast agent is unknown and may vary slightly between experiments and also within the vasculature because of its dependence on hematocrit. Inter- and intra-subject variations in blood concentration may be accounted for by the normalization of \( \Delta R_2^* \) to a reference region that is known to be insensitive to the treatment; however, this approach was not applicable here because of the systemic impact of the \( \alpha_1 \)-AR autoantibody. To adjust the contrast agent dose, the body weight was used as a surrogate of blood/plasma volume. The relationship between body weight and blood/plasma volume is very close: for Wistar rats, above 120 g body weight, the linear correlation is highly significant \((r = 0.99, n = 70)\) (39). Moreover, in this study, body weight was not significantly different between groups (e.g. 691 ± 17 g versus 677 ± 32 g, \( p = 0.70 \) at 9 months of treatment).

The MRI results prompted us to investigate whether the observed rCBV changes were reflected in changes in the cerebral blood vessels. We hypothesized that \textit{in vivo} rCBV findings at the final time point would correlate with \textit{ex vivo} immunohistological analyses of \( \alpha_1 \)-AR antibody-induced blood vessel impairments. After the last MRI time point, the rats were sacrificed and brain sections were analyzed with immunostaining. Quantitative analysis indeed showed significantly less CD31 \textsuperscript{+} blood vessel signal in the cerebral cortex of the \( \alpha_1 \)-AR group. Although these microscopic \textit{ex vivo} data showed a larger relative effect, rCBV is a macroscopic method that has been proven to have sufficient sensitivity to detect such rCBV effects \textit{in vivo} and non-invasively. The \textit{ex vivo} results support our \textit{in vivo} rCBV measurements, rule out that this was an entirely CVR-based effect and confirm deficiencies of the cerebral microvasculature in animals exposed to the \( \alpha_1 \)-AR antibody, which can be quantified non-invasively by MRI rCBV estimation.

**CONCLUSIONS**

The estimation of CBV by ferumoxytolate-enhanced steady-state MRI at 9.4T was successfully established and revealed a significant negative impact of \( \alpha_1 \)-adrenergic receptor antibodies on the cerebral microvasculature. rCBV was reduced in the cortex, hippocampus and, beyond that, in the dorsal cerebrum. Immunohistological analyses confirmed \( \alpha_1 \)-AR antibody-induced blood vessel deficiencies. These findings confirm the hypothesis that the \( \alpha_1 \)-AR antibody has effects reaching beyond previously reported macrovascular impairments in the predominantly extracranial major draining vessels of the rat brain (11) and leads to cerebral microvessel damage throughout the brain. This further underlines the suggested significance of this antibody in brain diseases linked to vasculature impairments, such as dementia.

**Acknowledgements**

This work was supported by the ProFIT program of the European Community (grant no. 10145576 to MB).
REFERENCES


SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher’s web site.